Otoba (Otoba parvifolia and Related Species): A Comprehensive Reference
1. Identity and Botanical Classification
Taxonomy and Nomenclature
Otoba parvifolia, commonly known as the Little Otoba, is a species of plants in the family Myristicaceae. Its current accepted name is Otoba parvifolia (Markgr.) A.H.Gentry, reflecting a taxonomic transfer made by botanist Alwyn Howard Gentry from the earlier classification as Dialyanthera parvifolia Markgr. Synonyms include Dialyanthera parvifolia Markgr. and Myristica otoba var. glaucescens A.DC.
The genus Otoba itself was originally described as Dialyanthera Warb., and its phytochemistry and ethnopharmacology were described in scholarly literature beginning with Gottlieb (1979), Martínez (2000), and Ferreira et al. (1989). Schultes and Holmstedt (1971) reported some ethnobotanical uses of Otoba (under the name Dialyanthera), and the phytochemistry and ethnopharmacology of Otoba was subsequently described by Gottlieb (1979), Martínez (2000), Ferreira et al. (1989), and De Wilde (2000).
Within the supplement and herbal product industry, O. parvifolia bark is most widely marketed under the commercial name Banderol. Otoba parvifolia bark is the botanical name of the herb used in Banderol, a tree native to the Amazon rainforest traditionally used in South American herbal medicine as an antimicrobial and for immune support; its common name includes Banderilla.
The Genus Otoba
Otoba is the third largest genus of Myristicaceae in the Neotropics with 12 accepted species, nine of them native to Colombia. The Myristicaceae, or nutmeg family, consists of 21 genera and about 500 species of dioecious canopy to sub-canopy trees distributed worldwide in tropical rainforests. Otoba is one of six genera of Myristicaceae native to the Neotropics.
The medically and commercially most relevant species are O. parvifolia and O. gracilipes, though the broader genus has attracted scientific attention for the whole range of species. Recognized species include O. acuminata, O. cyclobasis, O. glycycarpa, O. gordoniifolia, O. gracilipes, O. latialata, O. lehmannii, O. novogranatensis, O. parvifolia, and O. vespertilio, occurring from middle Central America through western Ecuador into the eastern parts of upper Amazonia.
Geographic Distribution
The native range of O. parvifolia is western South America to northern Venezuela; it is a tree that grows primarily in the wet tropical biome. Its range spans South America — Brazil, Bolivia, Peru, Ecuador, Colombia, and Venezuela. As currently delimited, the majority of Otoba species occur in the Andes of Colombia and Ecuador and the Chocó biogeographic region of Colombia and Ecuador, with eight and six species respectively; outside these regions, Peru, Bolivia, Venezuela, and Brazil are each home to two species.
The family's relatively large seeds, dispersed by large-bodied vertebrates, have contributed to its biogeographic spread; rapid niche evolution in Otoba has facilitated its occurrence throughout mesic habitats of the northern Neotropics, including the Amazon rainforest and Andean montane forests.
Morphology
Otoba parvifolia is a small tree native to the tropical regions of Central and South America, with a dense, rounded crown and dark green, glossy leaves. It is a tree whose bole can be unbranched for up to 30 metres. Otoba species have sessile or short-stalked malpighiaceous foliar trichomes; conduplicate vernation; staminate flowers with filaments fused in an elongated column with fused or free anthers; globose to ellipsoid green fruits; and seeds usually covered by a white aril. The Myristicaceae are of considerable ecological and ethnobotanical significance as they are important food for many animals and are harvested by humans for timber, spices, dart/arrow poison, medicine, and a hallucinogenic snuff employed in medico-religious ceremonies.
The common names used in the Spanish-speaking range are numerous. Regional common names include cuángare, cuángare blanco, cumalá blanca, cumala roja, otoba, otobo, sangre de toro, sangregallina, sangretoro, and sangrevaca.
2. Traditional and Historical Use
Indigenous Traditions of Northwestern South America
Plants of the genus Otoba have been the basis for the treatment of tropical diseases in indigenous communities of countries like Colombia. The species within this genus are well known in Latin American traditional medicine for their use against Chagas disease, leishmaniasis, malaria, and fungal and mite infections, among other applications.
A notable documented indigenous group is the Waorani of Ecuador. Otoba parvifolia, a Myristicaceae also growing in Central and South America, is traditionally used, for example, by the Waorani Indians from Ecuador, to treat infections caused by mites and fungi. The Waorani inhabit the eastern rainforest of Ecuador and represent one of the most ethnobotanically studied isolated Amazonian peoples; the Waorani Indians of eastern Ecuador are one of the least acculturated tribes in South America and hence provide a unique opportunity for studying the role of medicinal plants in an isolated Amazonian people.
Topical use of bark and resin was the primary traditional preparation. The bark and bright red resin are crushed and rubbed on the skin as a treatment for the bites of mites and fungal infections. The tree is harvested from the wild for local use as a medicine and as a source of wood.
Broader Neotropical Ethnobotanical Context
Within the Myristicaceae family, use of related species for dart poison, hallucinogenic preparations, and as spices in medico-religious contexts is well documented. The Myristicaceae are harvested by humans for timber, spices, dart/arrow poison, medicine, and a hallucinogenic snuff employed in medico-religious ceremonies. Though this characterization applies broadly to the family, the documented traditional uses of Otoba specifically are restricted in the peer-reviewed literature to antimicrobial and antiparasitic applications rather than to psychoactive preparations.
Ethnopharmacological use of the genus was first formally recorded in academic literature by Schultes and Holmstedt in 1971, using the then-current genus name Dialyanthera. Schultes and Holmstedt (1971) reported some ethnobotanical uses of Otoba (under the name Dialyanthera), and the phytochemistry and ethnopharmacology of Otoba was described by Gottlieb (1979), Martínez (2000), Ferreira et al. (1989), and De Wilde (2000).
Preparations and Forms in Traditional Use
Traditional preparations of O. parvifolia primarily involve the bark and its resinous exudate. The bright red resin that exudes from cuts in the bark is a characteristic feature of the plant and is applied topically for skin conditions including mite bites and fungal infections. Bark decoctions and maceration in water or alcohol for internal use are more recent practices tied to the broader diffusion of the plant's reputation in herbal medicine contexts.
3. Key Phytochemical Constituents and Active Compounds
Farnesyl-Homogentisic Acid Derivatives
The seeds of O. parvifolia have been the subject of detailed phytochemical investigation. The seeds of Otoba parvifolia contain six novel compounds apparently derived from homogentisic acid, including 3-farnesyl-2,5-dihydroxybenzaldehyde, 2-(1′-farnesyl-2′-hydroxy-5′-oxocyclohex-3′-en-1′-yl)-acetic acid lactone, 3-(1′-farnesyl-2′-hydroxy-4′-oxocyclopentan-1′-yl)-3-methoxy (and ethoxy) propanoic acid lactones and methyl esters. A follow-up study reported further novel members of this class: the seeds of O. parvifolia contain three additional novel compounds apparently derived from homogentisic acid: rel-(1′R,5′R)-2-(1′-farnesyl-5′-hydroxy-2′-oxocyclohex-3′-en-1′-yl)-acetic acid and its acetate, as well as rel-(1′R,4′S,5′R)-2-(1′-farnesyl-4′,5′-dihydroxy-2′-oxocyclohexan-1′-yl)-acetic acid δ-lactone. These farnesylated homogentisic acid derivatives are structurally distinctive to the genus and to related Myristicaceae.
Lignans
New spectral evidence was obtained for the known furofuran lignans xanthoxylol and phillygenol, isolated from the same seed source (O. parvifolia). The isolation of lignans from Myristica otoba (an older synonym) was reported by Nemethy et al. in Phytochemistry (1986). Furofuran lignans xanthoxylol and phillygenol were characterized using NMR and mass spectrometry from O. parvifolia seeds. Lignans are a broad class of phenylpropanoid dimers that, in other Myristicaceae, have been associated with antimicrobial, anti-inflammatory, and antioxidant activities.
Diarylpropanoids and Resorcinol-Type Compounds
The Myristicaceae family is characterized by an array of phenylpropanoid-derived metabolites. Malabaricone C from Myristica cinnamomea (a close relative within Myristicaceae) exhibits anti-quorum sensing activity, as reported in the Journal of Natural Products, 2011. While malabaricones have not been directly characterized from Otoba parvifolia in the accessible published literature, they represent a structurally relevant class within the broader family.
Endophyte-Associated Secondary Metabolites of O. gracilipes
Research on O. gracilipes, a closely related medicinal species from Colombia, has revealed an additional dimension of the pharmacologically relevant chemistry associated with the genus — through its endophytic fungi. Five fungal endophytes were isolated from the medicinal plant Otoba gracilipes (Myristicaceae), corresponding to the genera Xylaria and Diaporthe, and were screened for the production of bioactive secondary metabolites with broad-spectrum antibacterial activities. A new endophytic species was subsequently characterized: an isolate of Diaporthe, proven to represent a new species based on molecular data, was found to exhibit prominent antimicrobial effects and was prioritized for a metabolomics MS/MS-based investigation of its secondary metabolome; this led to the description of Diaporthe caliensis sp. nov., a systematic capture of its secondary metabolome, as well as an account of the biological properties of the isolated metabolites.
The polyketide lactone phomol (compound 1) was among the compounds identified from this endophyte of O. gracilipes. Researchers explored secondary metabolites produced by fungal endophytes of Otoba gracilipes (family Myristicaceae), a tropical medicinal tree not previously explored for potential bioactive metabolites.
General Phytochemical Classes
Based on the broader Myristicaceae literature, plants within the family characteristically contain terpenes, fatty acids, phenylpropanoids, lignans, flavonoids, and coumarins, among other secondary metabolites.
4. Scientific Evidence by Area of Use
4.1 Antimicrobial and Anti-Borrelia Activity
Background
Samento (extract from Uncaria tomentosa) and Banderol (extract from Otoba parvifolia) have been demonstrated to have anti-inflammatory and antimicrobial properties, for example against different morphological forms of Borrelia burgdorferi. The context in which Banderol/O. parvifolia has received the most laboratory-level investigation is the treatment of Lyme borreliosis, where the conventional antibiotic doxycycline is considered ineffective against certain dormant and biofilm forms of the causative spirochete.
In Vitro Anti-Borrelia Study (Datar et al., 2010)
The key laboratory study evaluating Banderol's activity against Borrelia burgdorferi was conducted by researchers from the Lyme Disease Research Group at the University of New Haven. In this study, two herbal extracts, Samento and Banderol, as well as doxycycline (one of the primary antibiotics for Lyme disease treatment), were tested for their in vitro effectiveness on several of the different morphological forms of B. burgdorferi (spirochetes, round bodies, and biofilm-like colonies) using fluorescent, darkfield microscopic, and BacLight viability staining methods.
In the presence of Banderol extracts, the size of colonies did not show any reduction; however, the cells inside the colonies were more than 90% dead. The results demonstrated that both herbal agents, but not doxycycline, had very significant effects on all forms of B. burgdorferi, especially when used in combination, suggesting that herbal agents could provide an effective therapeutic approach for Lyme disease.
The specific dilution regimens are relevant to understanding the effect. The maximum concentration used for both extracts was set to a dilution of 1:100; dilutions of 1:400 showed best activity against the round-body forms of Borrelia burgdorferi in vitro. When both extracts were combined: in the presence of extract from Otoba parvifolia, the size of biofilm colonies was not reduced; however, a bactericidal effect was achieved in more than 90%. In the presence of both herbal extracts, no sign of any colony formation was observed, with only a few nonmotile live spirochetes and rounded bodies.
Evidence strength: This is entirely in vitro evidence published in 2010 in the Townsend Letter, a peer-reviewed alternative medicine journal. No randomized controlled trials or other human clinical studies of O. parvifolia for Lyme disease have been published in the indexed peer-reviewed literature. While there is an increasing interest in studying antimicrobial properties of naturally derived agents, little is known about their effects against Borrelia burgdorferi sensu lato, the causative pathogens of Lyme disease. The in vitro results, while striking, cannot be translated to human efficacy claims without controlled clinical trials.
4.2 Antiprotozoal Activity
A systematic ethnopharmacological and chemotaxonomic investigation of Colombian plants evaluated Otoba species for antiprotozoal potential. In a search for therapeutic alternatives for antiprotozoal chemotherapy, researchers collected a selection of 44 plants from western Colombia. Polar and apolar extracts of these species were examined for antimalarial activity using in vitro tests with two clones of Plasmodium falciparum; leishmanicidal and trypanocidal activity were determined in vitro using promastigote and amastigote forms of several strains of Leishmania sp. and epimastigotes of Trypanosoma cruzi.
Among the selected plants, 15 species showed good or very good antiprotozoal activity in vitro; these included Otoba novogranatensis and Otoba parvifolia. Antiprotozoal activity for extracts of O. parvifolia has been demonstrated.
Evidence strength: In vitro only. The studies represent screening-level evidence that O. parvifolia extracts inhibit several protozoan parasites responsible for major tropical diseases (malaria, leishmaniasis, Chagas disease) under laboratory conditions. No animal efficacy models or human clinical trials have been reported in the indexed literature for any of these indications.
4.3 Antibacterial Activity of Endophytes
Investigations of endophytic fungi inhabiting O. gracilipes — a closely related medicinal Otoba species — have yielded organisms with demonstrated antibacterial activity. Five fungal endophytes were isolated from the medicinal plant Otoba gracilipes (Myristicaceae), corresponding to the genera Xylaria and Diaporthe; the evaluation of crude organic extracts obtained from the mycelia and exhaust medium demonstrated promising bioactivities against reference strains of Escherichia coli (ATCC 25922) and Staphylococcus aureus (ATCC 25923), with half-maximum inhibitory concentration (IC₅₀) values down to 3.91 and 10.50 mg/mL against each pathogen, respectively.
Evidence strength: Entirely in vitro, and the antibacterial activity described is that of the endophytic fungal extracts — organisms that inhabit the leaves of O. gracilipes — not of the plant itself. These findings are preliminary and exploratory.
4.4 Antioxidant Activity
Research on O. gracilipes leaves identified a fungal endophyte with measurable antioxidant activity. Tropical ecosystems hold an extremely diverse array of endophytic fungi; in one study, researchers isolated an endophytic fungus from the leaves of Otoba gracilipes, a medicinal tree from a tropical rainforest in Colombia, and evaluated its extracellular crude extract for antioxidant activity. The crude extract from the PDB (potato dextrose broth) culture had a DPPH scavenging activity of 51.5%, which was significantly higher than the PDYB (potato dextrose–yeast extract broth) culture (26.4%) (F₂ = 2,299.7; p < 0.001).
It is important to note that this high antioxidant activity was observed in the crude extracts of only one endophytic fungus isolated from a single plant species (Otoba gracilipes) from a particular tropical forest in Colombia.
Evidence strength: This is in vitro data generated from an endophytic fungal isolate, not from the plant itself. The results are preliminary and, as the authors noted, limited in their generalizability.
5. Body Systems and Health Areas of Association
Based on the documented traditional uses and laboratory evidence, the following body systems and health areas have been associated with Otoba species in the scientific and ethnobotanical literature:
- Immune system / Antimicrobial defense: Banderol (extract from Otoba parvifolia) has been demonstrated to have anti-inflammatory and antimicrobial properties, for example against different morphological forms of Borrelia burgdorferi.
- Tropical infectious disease (parasitology): The species within the Otoba genus are well known in Latin American traditional medicine for their use against Chagas, leishmaniasis, malaria, and fungal and mite infections, among other applications.
- Skin and integumentary system: The bark and bright red resin are traditionally crushed and rubbed on the skin as a treatment for the bites of mites and fungal infections.
- Anti-infective (Lyme disease context): In contemporary herbal medicine, O. parvifolia extract (Banderol) is used by some patients with chronic Lyme borreliosis as an adjunct to antibiotic therapy, a practice supported by in vitro but not human clinical evidence. Samento and Banderol are often used alternately or in addition to antibiotics by chronic borreliosis patients.
6. Dosage Forms and Reported Dosages
No human clinical trials establishing therapeutic doses of O. parvifolia have been published in the indexed peer-reviewed literature. Dosage information available in the literature is confined to in vitro study concentrations and manufacturer-recommended ranges described in published pharmacological safety research.
Commercial Liquid Extract (Banderol)
Banderol is an extract from Otoba parvifolia bark containing 20–24% ethanol.
In the in vitro herb-drug interaction study (Weiss, 2019), the pharmacologically relevant concentration context was described as follows: dilutions of 1:400 showed best activity against the round-body forms of Borrelia burgdorferi in vitro, whereas higher concentrations were only effective against the spirochete form; the manufacturer of Banderol recommends taking a maximum of 30 drops (= 1.5 mL) in about 100 mL water, representing a dilution of approximately 1:150 (0.7%).
As a general indication of how Banderol is used in practice, the following dosing recommendation appears in the available commercial literature, included here because it is cited in a peer-reviewed pharmacokinetic safety paper: the maximum manufacturer-recommended dose is 30 drops (approximately 1.5 mL) in water, up to several times daily, a dosage range referenced in the 2019 Weiss study published in Molecules.
Tincture Form
Tinctures of O. parvifolia bark are a common commercial form, typically prepared in distilled water and organic alcohol. One commercial preparation lists the composition as Otoba parvifolia (bark), distilled water, and organic alcohol at 55%.
7. Safety Considerations and Drug Interactions
General Safety Data Gaps
There is hardly any data on the pharmacological safety of Otoba parvifolia; the available in vitro study aimed at scrutinizing its possible characteristics as a perpetrator in pharmacokinetic herbal–drug interactions. No formal toxicological studies in animals or safety studies in humans have been published in the peer-reviewed literature for O. parvifolia specifically.
Transporter Inhibition: OATP1B1 and OATP1B3
The most specifically characterized safety concern for Banderol/O. parvifolia relates to hepatic drug transporters. Organic anion transporting polypeptide 1B1 (OATP1B1) (IC₅₀ = 0.49 ± 0.28%) and OATP1B3 (IC₅₀ = 0.65 ± 0.29%) were potently inhibited by Banderol, but only weakly by Samento. OATP1B1 and OATP1B3 are hepatic uptake transporters that mediate the liver extraction of numerous drugs, including statins (e.g., atorvastatin, simvastatin acid, rosuvastatin), certain antibiotics, and other medications. Inhibition of these transporters can elevate plasma concentrations of co-administered drugs, potentially increasing their toxicity.
CYP450 Enzyme Activity
Unlike Samento (Uncaria tomentosa extract), Banderol did not demonstrate significant inhibition of CYP450 enzymes or induction of major drug metabolizing enzymes. CYP3A4 was inhibited approximately 40% at a Samento concentration of 1%; Samento significantly induced mRNA expression of CYP2J2, UGT1A3, UGT1A9, ABCB1, and SLCO1B1 and strongly activated PXR; the perpetrator profiles of Samento and Banderol for herb–drug interactions completely differ.
P-glycoprotein (P-gp) and BCRP
No significant increase in intracellular calcein fluorescence by Banderol was observed in P-glycoprotein (P-gp) assays, verifying the lack of P-gp inhibition by the extract; breast cancer resistance protein (BCRP) was similarly neither inhibited by Samento nor by Banderol.
Clinical Relevance of In Vitro Interaction Data
The perpetrator profiles of Samento and Banderol for herb–drug interactions completely differ, and clinical studies are strongly recommended to clarify whether the effects observed in vitro are of clinical relevance. The OATP inhibition by Banderol, while measurable in cell-based systems, has not been evaluated in human pharmacokinetic studies, and the concentrations required for inhibition may or may not be achieved in the hepatic portal circulation following oral ingestion at recommended doses.
Drug Use Context and Co-medication Risks
Samento and Banderol are often used alternately or in addition to antibiotics by chronic borreliosis patients; for safe application, it is crucial to know whether the pharmacokinetics of concomitantly used drugs can be altered by these herbal extracts. The combination of Banderol with drugs that are substrates of OATP1B1 or OATP1B3 — such as certain statins, repaglinide, and various antibiotics — warrants attention in light of the in vitro transporter inhibition findings.
Conservation Status of O. gracilipes
Otoba gracilipes is one of the native medicinal plants from the Valle del Cauca River geographic area that is recently considered endangered (status: near threatened). While O. parvifolia itself has a broader range and is not reported as threatened, the conservation status of related species raises questions about the long-term sustainability of wild harvest for the genus.
8. Current State of Evidence and Research Limitations
The scientific investigation of Otoba parvifolia and related Otoba species remains at a very early stage. The biotechnological use of endophyte metabolites for pharmaceutical or agrochemical products is still in the developmental stage. The body of published research consists primarily of:
- Phytochemical characterization studies (seed chemistry — farnesyl-homogentisic acid derivatives, furofuran lignans)
- In vitro antimicrobial and antiprotozoal screening studies
- Studies of endophytic fungi associated with the medicinal plant
- A single in vitro pharmacokinetic drug interaction study (Weiss, 2019)
No peer-reviewed human clinical trials, animal efficacy models, or formal toxicological studies of the plant itself are indexed in PubMed or PMC at the time of this writing. Human clinical trials are very few across the Myristicaceae family; most pharmacological studies have not been conducted per current guidelines for natural products to ensure repeatability, safety, and translational use in human therapeutics; rigorous pharmacological evaluation and randomized double-blind clinical trials are recommended to analyze the efficacy and therapeutic potential of nutmeg and wild nutmegs. This characterization applies equally to Otoba.
References
Go back